Ar­row­head rocked by an­i­mal tox is­sues again, hit­ting the pause but­ton on RNAi study in cys­tic fi­bro­sis

Ar­row­head Phar­ma­ceu­ti­cals faced a reck­on­ing back in 2016 when it was forced to scrap its en­tire clin­i­cal pipeline af­ter re­port­ing deaths in a non-hu­man pri­mate tox­i­col­o­gy study. Now, years lat­er and with a dif­fer­ent de­liv­ery ve­hi­cle for its RNAi drugs, Ar­row­head faces an­i­mal tox is­sues again in what could be an­oth­er piv­otal set­back for its pipeline.

Ar­row­head has paused its Phase I/II tri­al of RNAi cys­tic fi­bro­sis drug ARO-ENaC af­ter a con­cur­rent chron­ic tox­i­col­o­gy study in rats turned up trou­bling lung in­flam­ma­tion sig­nals, the biotech said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER